| Price Range 12mo avg: | $940K – $6.3M |
|---|---|
| $/sf 12mo avg: | $376 |
| CAP Rate 12mo avg: | 6.87% |
| NOI average: | $193,167 |
| Lease Terms: | 15yrs NN |
| Building Size avg: | 8,000 SF |
| Lot Size avg: | 0.75+/- acres |
DaVita Kidney Care is a division of DaVita HealthCare Partners Inc., a Fortune 500® company that, through its operating divisions, provides a variety of health care services to patient populations throughout the United States and abroad. A leading provider of dialysis services in the United States, DaVita Kidney Care treats patients with chronic kidney failure and end stage renal disease. DaVita Kidney Care strives to improve patients’ quality of life by innovating clinical care, and by offering integrated treatment plans, personalized care teams and convenient health management services. As of September 30, 2015, DaVita Kidney Care operated or provided administrative services at 2,225 outpatient dialysis centers located in the United States serving approximately 177,000 patients. The company also operated 104 outpatient dialysis centers located in 10 countries outside the United States. DaVita Kidney Care supports numerous programs dedicated to creating positive, sustainable change in communities around the world. The company’s leadership development initiatives and social responsibility efforts have been recognized by Fortune, Modern Healthcare, Newsweek and WorldBlu.
DaVita—which is Italian for “giving life”—has more than 50,000 teammates (employees) around the nation working to provide superior patient care and exemplify the company’s Core Values
| S&P Credit Rating: | BB- |
|---|---|
| Moody’s Credit Rating: | Ba3 |
| Annual Revenue 2014: | $12.8B |
| Annual Revenue 2013: | $11.8B |
| Revenue Growth: | ↑ 8.13% from 2013 |
| Net Income | $723M |
| Units (Dec. 2014) | 2,179 |
| Average Units Volume: | $331856K |
Yahoo! Finance: DVA News Latest Financial News for DVA
-
Estimates and Recommendations for DaVita on September 17
on September 17, 2018 at 6:50 pm
Wall Street analysts estimate that DaVita (DVA) will report a 25.3% decline in revenues to $11.6 billion in 2018 compared to $15.5 billion in 2017. Its adjusted EPS is estimated at $4 in 2018 compared to $3.32 in 2017. Analysts estimate that its net adjusted income will increase to $693.4 million in 2018 compared to $634.9 million in 2017. […]
-
DaVita’s Quarterly Revenue Trend
on September 17, 2018 at 5:20 pm
DaVita (DVA) reported revenues of ~$2.9 billion in the second quarter of 2018, which is a 6.9% YoY (year-over-year) growth compared to $2.7 billion in the second quarter of 2017. DaVita reported 6.9% growth in its top line to $2.89 billion, including an 11.1% growth in revenues from US dialysis and related lab services to $2.57 billion, offset by a 17.7% decrease in revenues for other ancillary services and strategic initiatives in the second quarter of 2018. Medicare and Medicare Advantage revenues were $1.5 billion in the second quarter of 2018, a 16.2% growth compared to $1.3 billion in the second quarter of 2017. […]
-
DaVita’s Valuation on September 17
on September 17, 2018 at 3:45 pm
DaVita (DVA) is a biotechnology company focused on the discovery, development, and commercialization of specialist medicines to cater to the medical needs in rare diseases and other specialized conditions. DaVita reported non-GAAP EPS of $1.15 on revenues of $2.9 billion, a 6.9% growth YoY (year-over-year) compared to $2.7 billion in the second quarter of 2017. […]
-
DaVita Kidney Care Opens 150000-Square-Foot Campus in DeLand
on September 17, 2018 at 1:58 pm
DaVita's (DVA) dialysis care in the United States gets a boost; market prospects solid. […]
-
DaVita Labs to open 150,000-square-foot DeLand campus, add 100+ jobs
on September 13, 2018 at 10:06 pm
The company broke ground on the facility in the city's Northwest Industrial Business Park in 2016. […]
NYSE: DVA
